Comparative effectiveness of the monovalent XBB.1.5-containing covid-19 mRNA vaccine across three Nordic countries
Preprint
Abstract
Objective: To estimate the effectiveness of vaccination with a monovalent XBB.1.5-containing covid-19 mRNA vaccine against severe covid-19 across three Nordic countries. Design: Nationwide cohort studies, using target trial emulation. Setting: Denmark, Finland, and Sweden, from 1 October 2023 to 29 February 2024. Participants: Individuals aged ≥65 years who had previously received at least four covid-19 vaccine doses. Main outcome measures: Cumulative incidences of covid-19 hospital admission and death for 12 weeks after immunisation (defined as 1 week after vaccination) among recipients of an XBB.1.5-containing covid-19 mRNA vaccine and matched non-recipients. Cumulative incidences were used to calculate comparative vaccine effectiveness (1-risk ratio) and risk differences. Results: During autumn and winter 2023-2024, a total of 1,867,448 1:1 matched pairs of XBB-containing covid-19 mRNA vaccine recipients and non-recipients were included (mean age 75.4 years, standard deviation 7.4 years). The comparative vaccine effectiveness was 60.6% (95% confidence interval, 46.1% to 75.1%) against covid-19 hospital admission (930 v 2,551 events) and 77.9% (69.2% to 86.7%) against covid-19 related death (301 v 1,326 events) at 12 weeks of follow-up. This corresponded to 191.1 (95% confidence interval, 50.2 to 332.1) covid-19 hospital admissions and 109.2 (100.2 to 118.1) deaths prevented per 100,000 individuals vaccinated with an XBB.1.5-containing vaccine. The comparative vaccine effectiveness was similar across sex, age (65-74/≥75 years), number of previous covid-19 vaccine doses received, and seasonal influenza vaccination co-administration subgroups and periods of either omicron XBB- or BA.2.86-sublineage dominance. While the protection was highest during the first weeks after vaccination, it was well-preserved at end of week 12 of follow-up. Conclusion: Among adults aged ≥65 years, vaccination with a monovalent XBB.1.5-containing covid-19 mRNA vaccine reduced the rates of covid-19 related hospital admission and death during autumn and winter 2023-2024 across three Nordic countries.Keywords
This publication has 15 references indexed in Scilit:
- Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control studymedRxiv, 2024
- Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing VaccinesThe Journal of Infectious Diseases, 2024
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variantsbioRxiv, 2023
- Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analysesBMJ, 2023
- Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trialThe Lancet Regional Health - Europe, 2023
- Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workersClinical Microbiology and Infection, 2022
- Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health recordsBMJ, 2022
- Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label studyThe Lancet Respiratory Medicine, 2022
- Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialThe Lancet, 2021
- An extended mixed‐effects framework for meta‐analysisStatistics in Medicine, 2019